Bristol-Myers Squibb and partner 2seventy bio are facing a delay in their attempt to bring BCMA-directed CAR-T therapy Abecma to the US market as an earlier-line therapy f
Bayer has decided to discontinue a phase 3 trial of its oral Factor XIa inhibitor asundexian in patients with atrial fibrillation (AF), after an interim analysis concluded
Bayer has added another phase 3 trial into its registration programme for oral Factor XIa inhibitor asundexian, signalling growing confidence in a drug that generated mixe
GSK has set its sights on dominance of the market for hepatitis B virus (HBV) therapeutics, licensing an antisense oligonucleotide drug from Arrowhead Pharma and Johnson &
After an earlier rejection, the FDA has approved Eli Lilly’s first-in-class IL-23p19 inhibitor mirikizumab as a treatment for adults with moderately to severely active ulc
ViiV Healthcare and Johnson & Johnson have been granted approval in China for a long-acting HIV therapy that frees patients from the need to take daily pills to keep t